HHS seeks to re-identify de-identified HIPAA data

Jeff Byers | | Health Imaging | Artificial Intelligence
The Department of Health and Human Services (HHS) intends to solicit and award a task order contract to acquire services for the Office of the National Coordinator for Health IT (ONC), in order to re-identify a health Information Portability and Accountability (HIPAA) de-identified dataset.

According to HHS, the contractor should have an in-depth knowledge of the HIPAA Privacy Rule and experience with conducting research on re-identifying a HIPAA de-identified dataset. The agency said that the contractor shall take one or more HIPAA Privacy Rule de-identified datasets and demonstrate the ability or inability to re-identify the data.

HHS defines “re-identifying” as accurately and unambiguously matching the de-identifed data record to an actual individual.

No solicitation will be posted and capability statements are not being requested, stated the agency.

Jeff Byers

Related Content

AI beats standard regression models at predicting lung cancer risk
AI reduces CT lung cancer screening workload by nearly 80%
How AI and CCTA help heart teams plan ahead before PCI
5 steps for evaluating radiology AI applications
Adaptable AI system detects subtle changes in imaging, has potential across multiple clinical settings
New algorithm models radiologists' eye movements to interpret chest X-rays

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.